AdvaMed Weighs In On HCPCS Coding Process As CMS Considers Revisions
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers' inability to secure HCPCS codes for new technologies in a timely manner represents a threat to innovation, AdvaMed asserts in a June 10 letter to CMS
You may also be interested in...
HHS Med Tech Innovation Task Force To Issue Report By Year-End
Accelerated evolution of breakthrough medical technologies such as drug discovery tools, pharmacogenomics and analyte-specific reagents could result from a new HHS effort to better coordinate cross-department product development activities
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.